ESR1 and breast cancer: Because TNBC lacks the expression of ER, PR, and HER2 genes, compared with other BC types, it lacks corresponding therapeutic targets, is less sensitive to endocrine therapy, and has its unique biological characteristics, so the therapeutic effect is not good and patients' prognosis is poor [9].